Healthcare / BiotechnologyKOSDAQ
$2350.00
+10.00 (+0.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-5.8B · quality 70.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$74.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-13.4%
↓Gross Margin
43.2%
↓Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.8%
FCF CAGR
—
FCF margin
-26.3%
FCF / Net income
1.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $22.23B · net income $-3.22B · FCF $-5.85B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $22.23B | $22.23B | $22.26B | $18.79B | $13.95B |
| Net Income | $-3.22B | $-3.22B | $-3.89B | $-4.37B | $-10.08B |
| EBITDA | $-2.52B | $-2.52B | $-2.65B | $-3.93B | $-8.88B |
| EPS | -102.00 | -102.00 | -123.00 | -138.00 | -321.00 |
| Gross Margin | 43.2% | 43.2% | 42.8% | 31.4% | 10.7% |
| Operating Margin | -14.8% | -14.8% | -16.9% | -21.7% | -60.5% |
| Net Margin | -14.5% | -14.5% | -17.5% | -23.2% | -72.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.39 | 0.39 | 0.11 | 0.09 | 0.01 |
| Current Ratio | 1.95 | 1.95 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.85B | $-5.85B | $-2.45B | $-5.86B | $-5.75B |
| Returns | |||||
| ROE | -13.4% | -13.4% | -14.3% | -14.1% | -28.4% |
| Valuation | |||||
| P/B | 3.10 | 3.10 | 1.57 | 2.04 | 2.99 |
| Growth & Yield | |||||
| Revenue Growth | -0.2% | -0.2% | 18.5% | 34.7% | — |
| EPS Growth | 17.1% | 17.1% | 10.9% | 57.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-123.00 → -102.00
Residual
-3.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.